Arbutus Biopharma Corp reports results for the quarter ended in June - Earnings Summary

Arbutus Biopharma

03/08/2023 14:19

* Arbutus Biopharma Corp  ABUS.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 11 cents per share.
    * Revenue fell 67.3% to $4.65 million from a year ago;
analysts
expected $6.19 million. 
    * Arbutus Biopharma Corp's reported EPS for the quarter was
a loss
of 10 cents​.
    * The mean earnings estimate of analysts had risen by
about 15.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Arbutus Biopharma Corp shares had fallen by 9.6% this
quarter and lost 10.7% so far this year.
    * The company reported a quarterly loss of $17.09 million.
    * Wall Street's median 12-month price target for Arbutus
Biopharma
Corp is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 01:19 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.11          -0.10          Beat
 Mar. 31 2023      -0.14          -0.10          Beat
 Dec. 31 2022      -0.13          -0.14          Missed
 Sep. 30 2022      -0.13          -0.12          Beat